Izabela Guimaraes Barbosa1, Isabela Boechat Morato2, Aline Silva de Miranda2, Moisés Evandro Bauer3, Jair C Soares4, Antônio Lucio Teixeira5. 1. Laboratório Interdisciplinar de Investigação Médica da Faculdade de Medicina, Faculdade de Medicina, Universidade Federal de Minas Gerais, Alfredo Balena, 190, Room 281, Santa Efigênia, Belo Horizonte, MG, Brazil. Electronic address: izabelagb@gmail.com. 2. Laboratório Interdisciplinar de Investigação Médica da Faculdade de Medicina, Faculdade de Medicina, Universidade Federal de Minas Gerais, Alfredo Balena, 190, Room 281, Santa Efigênia, Belo Horizonte, MG, Brazil. 3. Laboratório de Imunologia do Envelhecimento, Instituto de Pesquisas Biomédicas, Pontifícia Católica Universidade do Rio Grande do Sul, Porto Alegre, Brazil. 4. Department of Psychiatry and Behavioral Sciences, UT Health School of Medicine, Houston, Texas, USA. 5. Laboratório Interdisciplinar de Investigação Médica da Faculdade de Medicina, Faculdade de Medicina, Universidade Federal de Minas Gerais, Alfredo Balena, 190, Room 281, Santa Efigênia, Belo Horizonte, MG, Brazil. Electronic address: altexr@gmail.com.
Abstract
BACKGROUND: Recent findings suggest an important role for inflammation in the neurobiology of bipolar disorder (BD). Interleukin 33 (IL-33) is a cytokine with multiple functions and may act as a nuclear factor regulating transcription and as an "alarmin". IL-33 exerts part of its function through the receptor ST2 that also exists in a soluble form (sST2). This study was performed to evaluate IL-33 and sST2 plasma levels in BD patients. METHODS: We evaluated IL33 and sST2 plasma levels of 46 BD patients (23 in euthymia and 23 in mania) and 23 healthy controls using enzyme-linked immunosorbent assay (ELISA). BD patients were age and gender matched healthy controls. RESULTS: IL-33 levels were higher in BD patients (p=0.02) but there was no difference in sST2 (p=0.55). IL33 and sST2 plasma levels were not correlated with age, neither was influenced by clinical comorbidities nor medications in use. CONCLUSION: These findings corroborate the view of BD as a multisystem condition with a proinflammatory profile.
BACKGROUND: Recent findings suggest an important role for inflammation in the neurobiology of bipolar disorder (BD). Interleukin 33 (IL-33) is a cytokine with multiple functions and may act as a nuclear factor regulating transcription and as an "alarmin". IL-33 exerts part of its function through the receptor ST2 that also exists in a soluble form (sST2). This study was performed to evaluate IL-33 and sST2 plasma levels in BD patients. METHODS: We evaluated IL33 and sST2 plasma levels of 46 BD patients (23 in euthymia and 23 in mania) and 23 healthy controls using enzyme-linked immunosorbent assay (ELISA). BD patients were age and gender matched healthy controls. RESULTS:IL-33 levels were higher in BD patients (p=0.02) but there was no difference in sST2 (p=0.55). IL33 and sST2 plasma levels were not correlated with age, neither was influenced by clinical comorbidities nor medications in use. CONCLUSION: These findings corroborate the view of BD as a multisystem condition with a proinflammatory profile.
Authors: Anastacia Y Kudinova; Terrence Deak; Cara M Hueston; John E McGeary; Valerie S Knopik; Rohan H C Palmer; Brandon E Gibb Journal: J Abnorm Psychol Date: 2016-04-07
Authors: Samira S Valvassori; Wilson R Resende; Roger B Varela; Camila O Arent; Fernanda F Gava; Bruna R Peterle; Gustavo C Dal-Pont; André F Carvalho; Monica L Andersen; João Quevedo Journal: Mol Neurobiol Date: 2017-02-06 Impact factor: 5.590
Authors: Jess G Fiedorowicz; Alan R Prossin; Casey P Johnson; Gary E Christensen; Vincent A Magnotta; John A Wemmie Journal: J Affect Disord Date: 2015-08-21 Impact factor: 4.839
Authors: K Becking; B C M Haarman; R F Riemersma van der Lek; L Grosse; W A Nolen; S Claes; H A Drexhage; R A Schoevers Journal: Int J Bipolar Disord Date: 2015-09-17